In March 2021, during the height of the COVID-19 pandemic, Contract Pharma wrote an article detailing Jubilant HollisterStier’s contract with Eli Lilly to manufacture a therapeutic COVID-19 treatment. This contract is one example of how JHS assisted in producing both treatments and vaccines during the pandemic.
In June of 2023, Chris Preti, CEO of Jubilant HollisterStier CMO, met with Grant Playter, associate editor of Pharmtech.com, at the 2023 DCAT Week conference. Topics of discussion include operations and the strategic vision at Jubliant HollisterStier, the current...
On March 16 2023, Contract Pharma sat down and interviewed Chris Preti, when he was appointed as president of Jubilant HollisterStier. Chris Preti has more than 25 years of pharmaceutical industry experience and has been the recent president of HollisterStier Allergy....
On July 14 2021, Fierce Pharma reported on the $76Mn expansion of the Jubilant HollisterStier CDMO facility in Montreal, Canada. This investment doubled the facility’s drug production capacity and added new, specialized equipment to be used in production.
